+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Meningococcal Vaccine"

Meningococcal Vaccines Market Report 2024-2034 - Product Thumbnail Image

Meningococcal Vaccines Market Report 2024-2034

  • Report
  • March 2024
  • 239 Pages
  • Global
From
From
Meningococcal Vaccines - Global Strategic Business Report - Product Thumbnail Image

Meningococcal Vaccines - Global Strategic Business Report

  • Report
  • March 2025
  • 194 Pages
  • Global
From
Meningococcal Vaccines Market Report 2025 - Product Thumbnail Image

Meningococcal Vaccines Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
Meningococcal Vaccines Market Report and Forecast 2024-2032 - Product Thumbnail Image

Meningococcal Vaccines Market Report and Forecast 2024-2032

  • Report
  • October 2024
  • 200 Pages
  • Global
From
From
From
Neisseria Meningitides Meningitis - Pipeline Insight, 2024 - Product Thumbnail Image

Neisseria Meningitides Meningitis - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 120 Pages
  • Global
From
Meningitis - Pipeline Insight, 2024 - Product Thumbnail Image

Meningitis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Mono Vaccine Market 2024-2028 - Product Thumbnail Image

Mono Vaccine Market 2024-2028

  • Report
  • July 2024
  • 139 Pages
  • Global
From
Anti-infective Vaccines Market Report 2023-2033 - Product Thumbnail Image

Anti-infective Vaccines Market Report 2023-2033

  • Report
  • September 2023
  • 303 Pages
  • Global
From
Meningitis Vaccines Market - Product Thumbnail Image

Meningitis Vaccines Market

  • Report
  • April 2019
  • 312 Pages
  • Global
From
From
From
From
Loading Indicator

The Meningococcal Vaccine is a type of vaccine used to protect against meningococcal disease, a serious and potentially fatal infection caused by the bacterium Neisseria meningitidis. It is recommended for adolescents and young adults, as well as for those at increased risk of infection, such as travelers to certain countries and those with certain medical conditions. The vaccine is available in both conjugate and polysaccharide forms, and is typically administered in two or three doses. The Meningococcal Vaccine market is part of the larger Infectious Diseases Drugs market, which includes a range of treatments for various infectious diseases. The Meningococcal Vaccine market is expected to grow in the coming years, driven by increasing awareness of the disease and the availability of new vaccines. Some companies in the Meningococcal Vaccine market include GlaxoSmithKline, Merck, Pfizer, Sanofi, and Novartis. Show Less Read more